Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen(®)

BACKGROUND: Filgrastim or methionyl-granulocyte colony-stimulating factor (Met-G-CSF), is a recombinant therapeutic protein widely used to treat severe neutropenia caused by myelosuppressive drugs in patients with nonmyeloid malignancies. In addition to its role in the regulation of granulopoiesis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Crobu, Davide, Spinetti, Gaia, Schrepfer, Rodolfo, Tonon, Giancarlo, Jotti, Gloria Saccani, Onali, Pierluigi, Dedoni, Simona, Orsini, Gaetano, Di Stefano, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942296/
https://www.ncbi.nlm.nih.gov/pubmed/24555723
http://dx.doi.org/10.1186/2050-6511-15-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942296/
https://www.ncbi.nlm.nih.gov/pubmed/24555723
http://dx.doi.org/10.1186/2050-6511-15-7

Ejemplares similares